Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $85.25 Average PT from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a consensus rating of “Moderate Buy” from the four brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $85.25.

A number of research analysts have issued reports on the stock. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research report on Monday, December 9th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. The trade was a 34.42 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB raised its stake in shares of Prestige Consumer Healthcare by 3.4% in the fourth quarter. Nordea Investment Management AB now owns 90,693 shares of the company’s stock worth $7,066,000 after buying an additional 2,985 shares during the period. GAMMA Investing LLC raised its stake in Prestige Consumer Healthcare by 18.9% during the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after acquiring an additional 220 shares during the period. JPMorgan Chase & Co. lifted its holdings in Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after purchasing an additional 8,533 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Prestige Consumer Healthcare by 4.3% in the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after purchasing an additional 894 shares in the last quarter. Finally, Sanctuary Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 11.0% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,248 shares of the company’s stock valued at $1,244,000 after purchasing an additional 1,715 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Down 0.8 %

NYSE:PBH opened at $73.91 on Friday. The firm has a market capitalization of $3.65 billion, a P/E ratio of 17.98, a P/E/G ratio of 2.32 and a beta of 0.51. Prestige Consumer Healthcare has a 52 week low of $58.18 and a 52 week high of $86.36. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The company has a fifty day moving average of $80.53 and a 200 day moving average of $74.14.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the business posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% on a year-over-year basis. On average, research analysts predict that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.